Company Overview
On 29 August 2024, Evolver Fund II acquired a controlling interest in Repolar Pharmaceuticals Oy. The company's founders, Arno Sipponen (MD, PhD), Lauri Sipponen, and Janne Jokinen (MD, PhD), remain significant shareholders. CEO Paavo Heikkinen also retains a shareholding and continues to lead the company.
Established in 2006 by the Sipponen family of doctors, Repolar researches, develops, manufactures and markets treatment products for humans and animals based on the active ingredients of spruce resin. The products are classified as self-care products and primarily aimed at wound treatment and skin care for both home and professional use. Repolar’s best-known product, Abilar® wound salve, can be found on the shelves of almost every Finnish pharmacy.
Repolar is based in Espoo, Finland and has a turnover of €3.2m (2023).
Key Facts
- Investment year: 2024
- Investor: Evolver Fund II
- Repolar is the Fund’s first investment.
Investment Rationale
With Evolver's support, Repolar will aim to accelerate growth and establish a strong position in the Nordic wound care market, as well as expand its footprint across European and global export markets.
“We are honored and excited to become part of Repolar’s growth journey and to support a business that connects nature, humans, and animals. We are deeply impressed by the pioneering spirit, passion, and scientific expertise that have driven the company's success to this point and look forward to supporting Paavo and his team in the internationalization of this Finnish success story.”
